[HTML][HTML] Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated …

RV Hewavisenti, J Arena, CL Ahlenstiel… - Frontiers in …, 2023 - frontiersin.org
Human papillomavirus (HPV), a common sexually transmitted virus infecting mucosal or
cutaneous stratified epithelia, is implicated in the rising of associated cancers worldwide …

Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer

C Chelimo, TA Wouldes, LD Cameron, JM Elwood - Journal of Infection, 2013 - Elsevier
Genital HPV infection is associated with development of cervical cancer, cervical neoplasia,
anogenital warts, and other anogenital cancers. A number of reviews have primarily …

2019 IUSTI‐Europe guideline for the management of anogenital warts

R Gilson, D Nugent, RN Werner… - Journal of the …, 2020 - Wiley Online Library
This guideline is an update of the 2011 European Guideline for the Management of
Anogenital Warts. It is intended to support best practice in the care of patients with …

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine

SM Garland, M Steben, HL Sings… - The Journal of …, 2009 - academic.oup.com
Background The placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …

[HTML][HTML] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and …

Future I/II Study Group - The BMJ, 2010 - ncbi.nlm.nih.gov
Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …

Human papillomavirus, human immunodeficiency virus and immunosuppression

LA Denny, S Franceschi, S de Sanjosé, I Heard… - Vaccine, 2012 - Elsevier
The vast majority of women infected with human immunodeficiency virus (HIV) will be co-
infected with human papillomavirus (HPV). The interaction between the two sexually …

[HTML][HTML] Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine

KP Braaten, MR Laufer - Reviews in obstetrics and gynecology, 2008 - ncbi.nlm.nih.gov
Human papillomavirus (HPV) is the most common sexually transmitted infection in the
United States, and persistent HPV infection is strongly associated with risk of cervical cancer …

Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

CJN Lacey, CM Lowndes, KV Shah - Vaccine, 2006 - Elsevier
Human Papillomavirus (HPV)-6 and-11 are the causative agents of ano-genital warts (GWs)
and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are …

The epidemiology of human papillomavirus infection and cervical cancer

FX Bosch, S de Sanjosé - Disease markers, 2007 - content.iospress.com
Cervical cancer has been recognized as a rare outcome of a common Sexually Transmitted
Infection (STI). The etiologic association is restricted to a limited number of viral types of the …